Remdesivir

Remdesivir (Veklury) is covered for treatment of SARS‑CoV‑2 infection to inhibit viral replication, including use in hospitalized adults and pediatric patients and for non‑hospitalized adults and pediatric patients at high risk for progression to severe COVID‑19. Coverage is limited to FDA‑approved indications per the product label with dosing consistent with authoritative sources, requires positive SARS‑CoV‑2 testing and administration in a hospital or equivalent acute‑care setting, and excludes non‑FDA‑approved or unsupported off‑label uses and patients below label age/weight thresholds.

"Requested therapies must be proven effective for the relevant diagnosis or procedure."

Sign up to see full coverage criteria, indications, and limitations.